Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3700283rdf:typepubmed:Citationlld:pubmed
pubmed-article:3700283lifeskim:mentionsumls-concept:C0014806lld:lifeskim
pubmed-article:3700283lifeskim:mentionsumls-concept:C0282563lld:lifeskim
pubmed-article:3700283lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:3700283lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:3700283lifeskim:mentionsumls-concept:C0750743lld:lifeskim
pubmed-article:3700283pubmed:issue2lld:pubmed
pubmed-article:3700283pubmed:dateCreated1986-5-23lld:pubmed
pubmed-article:3700283pubmed:abstractTextThe activity of a novel macrolide, RU 28965, was compared to that of erythromycin against Gram-positive organisms isolated mainly from cancer patients. RU 28965 was active against streptococci including Streptococcus pneumoniae and streptococcal groups A, B and G. It was also active against methicillin-susceptible staphylococci, Bacillus cereus and Listeria monocytogenes. Its activity against these organisms was generally equal to that of erythromycin. RU 28965 was moderately active against enterococci and inactive against JK diphtheroids and three different species of coagulase-negative staphylococci. Organisms resistant to erythromycin were also resistant to RU 28965.lld:pubmed
pubmed-article:3700283pubmed:languageenglld:pubmed
pubmed-article:3700283pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3700283pubmed:citationSubsetIMlld:pubmed
pubmed-article:3700283pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3700283pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3700283pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3700283pubmed:statusMEDLINElld:pubmed
pubmed-article:3700283pubmed:monthFeblld:pubmed
pubmed-article:3700283pubmed:issn0305-7453lld:pubmed
pubmed-article:3700283pubmed:authorpubmed-author:HoD HDHlld:pubmed
pubmed-article:3700283pubmed:authorpubmed-author:LeBlancBBlld:pubmed
pubmed-article:3700283pubmed:authorpubmed-author:RolstonK VKVlld:pubmed
pubmed-article:3700283pubmed:issnTypePrintlld:pubmed
pubmed-article:3700283pubmed:volume17lld:pubmed
pubmed-article:3700283pubmed:ownerNLMlld:pubmed
pubmed-article:3700283pubmed:authorsCompleteYlld:pubmed
pubmed-article:3700283pubmed:pagination161-3lld:pubmed
pubmed-article:3700283pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3700283pubmed:meshHeadingpubmed-meshheading:3700283-...lld:pubmed
pubmed-article:3700283pubmed:meshHeadingpubmed-meshheading:3700283-...lld:pubmed
pubmed-article:3700283pubmed:meshHeadingpubmed-meshheading:3700283-...lld:pubmed
pubmed-article:3700283pubmed:meshHeadingpubmed-meshheading:3700283-...lld:pubmed
pubmed-article:3700283pubmed:meshHeadingpubmed-meshheading:3700283-...lld:pubmed
pubmed-article:3700283pubmed:meshHeadingpubmed-meshheading:3700283-...lld:pubmed
pubmed-article:3700283pubmed:meshHeadingpubmed-meshheading:3700283-...lld:pubmed
pubmed-article:3700283pubmed:year1986lld:pubmed
pubmed-article:3700283pubmed:articleTitleIn-vitro activity of RU 28965, a new macrolide, compared to that of erythromycin.lld:pubmed
pubmed-article:3700283pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3700283pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3700283lld:pubmed